Company Vidac Pharma Holding Plc

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company. It is focused on discovering and developing medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. It develops anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize the tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. Its pipeline includes VDA-1102 Ointment, VDA-1102 IV and VDA-1275. VDA-1102 ointment is a drug that selectively targets malignant cutaneous cells with minimal effects on surrounding healthy skin. VDA-1102 IV is an anti-neoplastic agent that utilizes a mechanism of action involving selective modulation of VDAC/HK2. VDA-1275 is a potent small molecule new chemical entity (NCE) with a mechanism of action that selectively modulates VDAC/HK2 interaction.